FTC wants to know: How are PBMs af­fect­ing drug af­ford­abil­i­ty and ac­cess?

Fol­low­ing the Fed­er­al Trade Com­mis­sion’s de­ci­sion to not, at least ini­tial­ly, dig deep­er in­to phar­ma mid­dle­men known as PBMs, the com­mis­sion is now seek­ing com­ments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER